X Lin1, Z Wang, R Zhang, W Feng. 1. Department of Paediatric Intensive Care Units, Huai'an Maternity and Child Health Hospital of Yangzhou University, Huai'an, 223002, Jiangsu Province, China.
Abstract
PURPOSE: MiRNA expression profiles previously showed the higher expression of microRNA(miR)-335 in bone marrow samples of pediatric acute myeloid leukemia (AML) patients than normal controls. Our aim was to investigate associations of miR-335 expression with tumor progression and prognosis in pediatric AML. METHODS: Real-time quantitative PCR was performed to detect the expression of miR-335 in bone marrow mononuclear cells and serum obtained from patients with pediatric AML and healthy controls. RESULTS: Expression levels of miR-335 in the bone marrow and serum of pediatric AML patients were both significantly higher than those in normal controls (both P < 0.001). Then, high serum miR-335 level occurred more frequently in French-American-British classification subtype M7 subtype than in other subtypes (P = 0.03). The expression of serum miR-335 in pediatric AML patients with unfavorable karyotypes was also significantly higher than those in intermediate and favorable groups (P = 0.008). Moreover, high serum miR-335 level was markedly associated with shorter relapse-free and overall survivals (both P < 0.001) of patients with pediatric AML. Furthermore, the multivariate analysis identified the serum miR-335 and cytogenetics risk as independent prognostic factors for both relapse-free and overall survivals. More importantly, the prognostic relevance of serum miR-335 expression was more obvious in the subgroup of patients with intermediate-risk cytogenetics. CONCLUSION: Our data offer the convincing evidence for the first time that serum miR-335 level may be markedly and consistently increased in pediatric AML patients. Serum miR-335 may serve as a promising marker for monitoring the progression and predicting the clinical outcome of patients with this disease.
PURPOSE: MiRNA expression profiles previously showed the higher expression of microRNA(miR)-335 in bone marrow samples of pediatric acute myeloid leukemia (AML) patients than normal controls. Our aim was to investigate associations of miR-335 expression with tumor progression and prognosis in pediatric AML. METHODS: Real-time quantitative PCR was performed to detect the expression of miR-335 in bone marrow mononuclear cells and serum obtained from patients with pediatric AML and healthy controls. RESULTS: Expression levels of miR-335 in the bone marrow and serum of pediatric AMLpatients were both significantly higher than those in normal controls (both P < 0.001). Then, high serum miR-335 level occurred more frequently in French-American-British classification subtype M7 subtype than in other subtypes (P = 0.03). The expression of serum miR-335 in pediatric AMLpatients with unfavorable karyotypes was also significantly higher than those in intermediate and favorable groups (P = 0.008). Moreover, high serum miR-335 level was markedly associated with shorter relapse-free and overall survivals (both P < 0.001) of patients with pediatric AML. Furthermore, the multivariate analysis identified the serum miR-335 and cytogenetics risk as independent prognostic factors for both relapse-free and overall survivals. More importantly, the prognostic relevance of serum miR-335 expression was more obvious in the subgroup of patients with intermediate-risk cytogenetics. CONCLUSION: Our data offer the convincing evidence for the first time that serum miR-335 level may be markedly and consistently increased in pediatric AMLpatients. Serum miR-335 may serve as a promising marker for monitoring the progression and predicting the clinical outcome of patients with this disease.
Authors: Kim J Png; Mitsukuni Yoshida; Xiang H-F Zhang; Weiping Shu; Hyeseung Lee; Andreas Rimner; Timothy A Chan; Elizabeth Comen; Viktor P Andrade; Seok Won Kim; Tari A King; Clifford A Hudis; Larry Norton; James Hicks; Joan Massagué; Sohail F Tavazoie Journal: Genes Dev Date: 2011-02-01 Impact factor: 11.361
Authors: Alberto Izzotti; Stefano Carozzo; Alessandra Pulliero; Dinara Zhabayeva; Jean Louis Ravetti; Rakhmet Bersimbaev Journal: Am J Cancer Res Date: 2016-07-01 Impact factor: 6.166
Authors: Emilia L Lim; Diane L Trinh; Rhonda E Ries; Jim Wang; Robert B Gerbing; Yussanne Ma; James Topham; Maya Hughes; Erin Pleasance; Andrew J Mungall; Richard Moore; Yongjun Zhao; Richard Aplenc; Lillian Sung; E Anders Kolb; Alan Gamis; Malcolm Smith; Daniela S Gerhard; Todd A Alonzo; Soheil Meshinchi; Marco A Marra Journal: J Clin Oncol Date: 2017-10-25 Impact factor: 44.544